多西紫杉醇联合顺铂治疗晚期非小细胞肺癌32例疗效观察  

Clinical efficacy of docetaxel and cisplatin in the treatment for 32 cases with advanced non-small cell lung cancer

作　　者：王凤庭[1] 郑红霞[1] 

机构地区：[1]云南省曲靖市第一人民医院肿瘤科,云南曲靖655000

出　　处：《现代肿瘤医学》2007年第1期40-41,共2页Journal of Modern Oncology

摘　　要：目的：观察多西紫杉醇（docetaxel，TXT）＋顺铂（cisplatin，DDP）联合治疗晚期非小细胞肺癌（NSCLC）的临床疗效和毒副作用。方法：对32例晚期NSCLC患者采用TXT联合DDP方案化疗：TXT35mg／m^2，ivgtt，d1，8，15；DDP25mg／m^2，ivgtt，d1～3，每28天重复，至少治疗2个周期。结果：总有效率46．9％，中位生存期11．3个月，主要毒副作用为骨髓抑制、脱发、恶心和呕吐。结论：TXT联合DDP治疗晚期NSCLC有较好疗效，毒副作用可以耐受。Objective： To evaluate the clinical efficacy and side effects of combination chemotherapy with docetaxel plus cisplatin in the treatment of advanced non -small cell lung cancer （NSCLC）. Methods： Thirty - two patients with unresectable NSCLC were enrolled into this study. Docetaxel was administered 35mg/m^2 d1,8, 15, cisplatin 25 mg/m^2 d1 - 3. Two or more therapatic courses were conducted with an interval of 28 days. Results： The total responsive rate was 46.9%, median survival time was 11.3 months. The side effects were slight, including myelosuppression, baldness, nausea and vomiting. Conclusion： The schedule of docetaxel and cisplatin for advanced NSCLC has good clinical efficacy.

关 键 词：非小细胞肺癌 多西紫杉醇(艾素) 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]